USA flag logo/image

An Official Website of the United States Government

In-vitro culture of Plasmodium falciparum sporozoites for malaria vaccine

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
95737
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
AI085740
Solicitation Year:
N/A
Solicitation Topic Code:
NIAID
Solicitation Number:
N/A
Small Business Information
SANARIA, INC.
9800 Medical Center Dr. ste A209 ROCKVILLE, MD 20850
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: In-vitro culture of Plasmodium falciparum sporozoites for malaria vaccine
Agency: HHS
Contract: 1R43AI085740-01
Award Amount: $569,920.00
 

Abstract:

DESCRIPTION (provided by applicant): The recent call for elimination of malaria caused by Plasmodium falciparum (Pf) and eventual eradication of all malaria has focused attention on this disease, which is responsible for hundreds of millions of cases and a million deaths annually. An ideal tool for eliminating Pf, the causative agent of 99% of all malaria deaths, would be a highly effective vaccine that prevents blood stage infection and thereby prevents all disease and transmission. When attenuated Pf spor ozoites (PfSPZ) are administered by the bite of infected mosquitoes, gt 90% of human volunteers are protected against experimental Pf challenge and protection lasts at least 10 months. Sanaria's goal is to develop and commercialize an attenuated PfSPZ vacc ine that prevents Pf blood stage infection in gt 90% of recipients; a vaccine that could be used to eliminate Pf from the world. This vaccine has the potential for gt 1 billion annual revenues in markets in the developed and developing world. Sanaria has succeeded in establishing robust, reproducible, and consistent manufacture and release of clinical lots of its PfSPZ Vaccine, received FDA approval to proceed with clinical trials (IND approval), and in the 2nd quarter of 2009 will be initiating a Phase 1 clinical trial to assess safety, immunogenicity, and protective efficacy of the PfSPZ Vaccine. After demonstrating safety in that trial, the goal is to move as swiftly as possible to safety and proof of concept efficacy studies in African adults, young chi ldren, and infants. These will be followed by additional Phase 2 studies, including dose optimization studies, and then pivotal Phase 3 studies to support licensure. There is a clearcut path to taking such a mosquito-produced vaccine forward to registratio n and commercialization. However, it would be ideal if the sporozoites could be produced in culture instead of in mosquitoes. After a mosquito ingests malaria parasites called gametocytes when feeding on humans, the parasite develops in the mosquito from t he gametoctyes into gametes, zygotes, ookinetes, and finally oocysts containing sporozoites. Pf oocysts containing sporozoites were produced in culture in 1993, but the finding was never replicated, primarily because it was not possible to reproducibly pro duce Pf ookinetes in culture. Infective P. berghei sporozoites have been produced in culture. It is the goal of this project to establish a method of producing in culture Pf sporozoites that can be used in an attenuated sporozoite vaccine. This method of p roduction would eliminate the need for producing sporozoites in mosquitoes. The major impediment to utilizing the system established in 2002 for producing P. berghei sporozoites in vitro to produce Pf sporozoites in vitro has been the capacity to produce l arge quantities of viable Pf ookinetes. This limitation has now been overcome. In the 1st 6 months of this project we will optimize ookinete production and purification. Subsequently we will use Pf ookinetes to optimize production of Pf sporozoites in vitr o, and demonstrate infectivity of these sporozoites to human hepatocytes in vitro. The long term goal is to deliver a method to produce in vitro Pf sporozoites for use in an attenuated Pf sporozoite vaccine. PUBLIC HEALTH RELEVANCE: A highly effecti ve malaria vaccine would have an enormous public health benefit. Sanaria's attenuated malaria sporozoite vaccine (PfSPZ Vaccine) is expected to be highly effective and will be studied in clinical trials in 2009. The PfSPZ Vaccine is manufactured in mosquit oes. This research aims to eliminate the need for mosquitoes in manufacturing the PfSPZ Vaccine.

Principal Investigator:

Stephen L. Hoffman
3017703222
SLHOFFMAN@SANARIA.COM

Business Contact:

Thompson
rcthompson@sanaria.com
Small Business Information at Submission:

SANARIA, INC.
9800 Medical Center Dr. ste A209 ROCKVILLE, MD -

EIN/Tax ID: 156235436
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No